CLINICAL TRIAL

CFZ533 for Sicca Syndrome

Recruiting · 18+ · All Sexes · Budapest, Hungary

This study is evaluating whether a drug may help treat Sjögren's syndrome.

See full description

About the trial for Sicca Syndrome

Eligible Conditions
Sjogren's Syndrome · Syndrome · Sjögren's Syndrome

Treatment Groups

This trial involves 8 different treatments. CFZ533 is the primary treatment being studied. Participants will be divided into 6 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Experimental Group 1
CFZ533
DRUG
Experimental Group 2
CFZ533
DRUG
Experimental Group 3
CFZ533
DRUG
Show More

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iscalimab
Not yet FDA approved

Side Effect Profile for CFZ533 + TAC + MMF (Part 1)

CFZ533 + TAC + MMF (Part 1)
Show all side effects
71%
Hypophosphataemia
57%
Nausea
43%
Hyperglycaemia
43%
BK virus infection
43%
Dyspnoea
43%
Vomiting
43%
Secretion discharge
43%
Incision site pain
29%
Tremor
29%
Tachycardia
29%
Vitamin D deficiency
29%
Diarrhoea
29%
Oedema peripheral
29%
Hyperparathyroidism secondary
29%
Eye movement disorder
29%
Dyspepsia
29%
Hypomagnesaemia
14%
Headache
14%
Nocturia
14%
Leukocytosis
14%
Pain
14%
Hyperkalaemia
14%
Anxiety
14%
Groin pain
14%
Acne
14%
Aphthous ulcer
14%
Alopecia
14%
Photophobia
14%
Hypertension
14%
Insomnia
14%
Pancreatitis
14%
Complications of transplanted kidney
14%
Pulmonary embolism
14%
Paraesthesia oral
14%
Hyperlipidaemia
14%
Hypokalaemia
14%
Dizziness postural
14%
Anaemia
14%
Leukopenia
14%
Incision site erythema
14%
Radius fracture
14%
Electrocardiogram ST segment abnormal
14%
Dizziness
14%
Paraesthesia
14%
Productive cough
14%
Orthostatic hypotension
14%
Abdominal pain
14%
Vision blurred
14%
Mouth ulceration
14%
White blood cell count decreased
14%
Deep vein thrombosis
14%
Nasopharyngitis
14%
Constipation
14%
Fatigue
14%
Generalised oedema
14%
Influenza like illness
14%
Urinary tract infection
14%
Complications of transplant surgery
14%
Cardiac murmur
14%
Blood phosphorus decreased
14%
Weight decreased
14%
Muscle spasms
14%
Phonophobia
14%
Dysuria
14%
Micturition urgency
14%
Wheezing
14%
Abdominal distension
0%
Incarcerated incisional hernia
0%
Hyperuricaemia
0%
Pneumocystis jirovecii pneumonia
0%
Otitis media
0%
Polycythaemia
0%
Urosepsis
0%
Myocardial infarction
0%
Asthenia
0%
Ocular hyperaemia
0%
Pneumonia
0%
Amylase increased
0%
Lymphocele
0%
Acute sinusitis
0%
Infection
0%
Oral infection
0%
Pyelonephritis
0%
Tooth infection
0%
Wound haematoma
0%
Ataxia
0%
Perinephric collection
0%
Penile pain
0%
Myalgia
0%
White blood cell count increased
0%
Burning sensation
0%
Haematoma
0%
Hot flush
0%
Pneumothorax
0%
Dehydration
0%
Atrial fibrillation
0%
Urinary retention
0%
Soft tissue infection
0%
Weight increased
0%
Haemoglobin decreased
0%
Gingival pain
0%
Oesophagitis
0%
Kidney transplant rejection
0%
Cytomegalovirus viraemia
0%
Lung infection
0%
Respiratory tract infection
0%
Incision site haemorrhage
0%
Hypervolaemia
0%
Cough
0%
Lung infiltration
0%
Oral candidiasis
0%
Polyomavirus-associated nephropathy
0%
Wound infection bacterial
0%
Graft complication
0%
Drug level decreased
0%
Diarrhoea haemorrhagic
0%
Transplant dysfunction
0%
Renal cyst infection
0%
Abdominal discomfort
0%
Inguinal hernia
0%
Gastritis haemorrhagic
0%
Chills
0%
Oral herpes
0%
Gastroenteritis
0%
Hepatitis
0%
Epstein-Barr virus infection
0%
Human polyomavirus infection
0%
Mucocutaneous candidiasis
0%
Latent tuberculosis
0%
Incisional hernia
0%
Pain in extremity
0%
Decubitus ulcer
0%
Poor venous access
0%
Hyperphosphataemia
0%
Mood swings
0%
Flatulence
0%
Delayed graft function
0%
Fall
0%
Hypercholesterolaemia
0%
Muscle twitching
0%
Palpitations
0%
Retroperitoneal haematoma
0%
Subcutaneous abscess
0%
Proteinuria
0%
Diarrhoea infectious
0%
Gastritis
0%
Cytomegalovirus test positive
0%
Dyslipidaemia
0%
Delirium
0%
Enterobacter bacteraemia
0%
Squamous cell carcinoma
0%
Arteriovenous fistula aneurysm
0%
Catheter site pain
0%
Herpes zoster
0%
Sinusitis
0%
Influenza
0%
Postoperative wound complication
0%
Gamma-glutamyltransferase increased
0%
Increased appetite
0%
Metabolic acidosis
0%
Neck pain
0%
Osteochondrosis
0%
Renal tubular acidosis
0%
Tubulointerstitial nephritis
0%
Dyspnoea exertional
0%
Encephalitis
0%
Infusion site swelling
0%
Gastroenteritis viral
0%
Fungal skin infection
0%
Hyperparathyroidism
0%
Conjunctivitis
0%
Joint injury
0%
Hypocalcaemia
0%
Arthralgia
0%
Renal tubular injury
0%
Rhinorrhoea
0%
Hydrocele
0%
Cytomegalovirus infection
0%
Ileus
0%
Gastroenteritis norovirus
0%
Incision site complication
0%
Back pain
0%
Penile oedema
0%
Renal tubular necrosis
0%
Pelvic venous thrombosis
0%
Iron deficiency anaemia
0%
Neutropenia
0%
Ear discomfort
0%
Vertigo
0%
Dry eye
0%
Retinal vein occlusion
0%
Dysphagia
0%
Gingival recession
0%
Malaise
0%
Peripheral swelling
0%
Bronchitis
0%
Folliculitis
0%
Gastroenteritis Escherichia coli
0%
Skin infection
0%
Tinea versicolour
0%
Upper respiratory tract infection
0%
Arterial injury
0%
Ligament sprain
0%
Aspartate aminotransferase increased
0%
Electrocardiogram T wave abnormal
0%
Diabetes mellitus
0%
Hypertriglyceridaemia
0%
Magnesium deficiency
0%
Flank pain
0%
Migraine
0%
Peroneal nerve palsy
0%
Bladder spasm
0%
Haematuria
0%
Renal impairment
0%
Pleural effusion
0%
Respiratory distress
0%
Heart rate irregular
0%
Hypertensive crisis
0%
Pancytopenia
0%
Tricuspid valve incompetence
0%
Gastrointestinal inflammation
0%
Bacteraemia
0%
Gastrointestinal infection
0%
Hepatitis C
0%
Transplant failure
0%
Graft loss
0%
Acute kidney injury
0%
Blood creatinine increased
0%
Basosquamous carcinoma
0%
Mental status changes
0%
Angina pectoris
0%
Arrhythmia
0%
Normocytic anaemia
0%
Lymphopenia
0%
Microcytic anaemia
0%
Thrombocytosis
0%
Nephrogenic anaemia
0%
Thrombocytopenia
0%
Bradycardia
0%
Extrasystoles
0%
Sinus tachycardia
0%
Chalazion
0%
Abdominal pain lower
0%
Abdominal pain upper
0%
Gingival swelling
0%
Anal fissure
0%
Colitis
0%
Duodenogastric reflux
0%
Gastric polyps
0%
Haemorrhoids
0%
Pharyngitis streptococcal
0%
Odynophagia
0%
Stomatitis
0%
Tongue discomfort
0%
Cyst
0%
Impaired healing
0%
Pyrexia
0%
Drug hypersensitivity
0%
Hepatomegaly
0%
Swelling
0%
Hepatic function abnormal
0%
Pyuria
0%
Laryngitis
0%
Rhinitis
0%
Tracheobronchitis
0%
Viral infection
0%
Animal bite
0%
Urinary tract infection viral
0%
Arthropod bite
0%
Arteriovenous fistula site complication
0%
Post procedural complication
0%
Lip injury
0%
Post procedural swelling
0%
Post procedural haemorrhage
0%
Procedural pain
0%
Wound complication
0%
Alanine aminotransferase increased
0%
Seroma
0%
Wound dehiscence
0%
Blood creatine phosphokinase increased
0%
Blood glucose increased
0%
Blood lactate dehydrogenase increased
0%
Blood phosphorus increased
0%
C-reactive protein increased
0%
Lipase increased
0%
Polyomavirus test positive
0%
Vitamin D decreased
0%
Decreased appetite
0%
Fluid overload
0%
Folate deficiency
0%
Hypercalcaemia
0%
Hyponatraemia
0%
Bursitis
0%
Hypercreatinaemia
0%
Joint effusion
0%
Muscular weakness
0%
Musculoskeletal discomfort
0%
Pain in jaw
0%
Basal cell carcinoma
0%
Hypoaesthesia
0%
Polyneuropathy
0%
Restlessness
0%
Bladder pain
0%
Chronic kidney disease
0%
Leukocyturia
0%
Perinephric oedema
0%
Polyuria
0%
Sterile pyuria
0%
Urethral pain
0%
Urinary incontinence
0%
Urinary tract disorder
0%
Urinary tract obstruction
0%
Benign prostatic hyperplasia
0%
Dysmenorrhoea
0%
Erectile dysfunction
0%
Menorrhagia
0%
Prostatomegaly
0%
Scrotal swelling
0%
Vulvovaginal pain
0%
Nasal congestion
0%
Oropharyngeal pain
0%
Sleep apnoea syndrome
0%
Dermatitis
0%
Hyperhidrosis
0%
Lipohypertrophy
0%
Night sweats
0%
Pityriasis
0%
Pruritus
0%
Rash
0%
Skin lesion
0%
Urticaria
0%
Hypotension
0%
Transplant rejection
Hypophosphataemia
71%
Nausea
57%
Hyperglycaemia
43%
BK virus infection
43%
Dyspnoea
43%
Vomiting
43%
Secretion discharge
43%
Incision site pain
43%
Tremor
29%
Tachycardia
29%
Vitamin D deficiency
29%
Diarrhoea
29%
Oedema peripheral
29%
Hyperparathyroidism secondary
29%
Eye movement disorder
29%
Dyspepsia
29%
Hypomagnesaemia
29%
Headache
14%
Nocturia
14%
Leukocytosis
14%
Pain
14%
Hyperkalaemia
14%
Anxiety
14%
Groin pain
14%
Acne
14%
Aphthous ulcer
14%
Alopecia
14%
Photophobia
14%
Hypertension
14%
Insomnia
14%
Pancreatitis
14%
Complications of transplanted kidney
14%
Pulmonary embolism
14%
Paraesthesia oral
14%
Hyperlipidaemia
14%
Hypokalaemia
14%
Dizziness postural
14%
Anaemia
14%
Leukopenia
14%
Incision site erythema
14%
Radius fracture
14%
Electrocardiogram ST segment abnormal
14%
Dizziness
14%
Paraesthesia
14%
Productive cough
14%
Orthostatic hypotension
14%
Abdominal pain
14%
Vision blurred
14%
Mouth ulceration
14%
White blood cell count decreased
14%
Deep vein thrombosis
14%
Nasopharyngitis
14%
Constipation
14%
Fatigue
14%
Generalised oedema
14%
Influenza like illness
14%
Urinary tract infection
14%
Complications of transplant surgery
14%
Cardiac murmur
14%
Blood phosphorus decreased
14%
Weight decreased
14%
Muscle spasms
14%
Phonophobia
14%
Dysuria
14%
Micturition urgency
14%
Wheezing
14%
Abdominal distension
14%
Incarcerated incisional hernia
0%
Hyperuricaemia
0%
Pneumocystis jirovecii pneumonia
0%
Otitis media
0%
Polycythaemia
0%
Urosepsis
0%
Myocardial infarction
0%
Asthenia
0%
Ocular hyperaemia
0%
Pneumonia
0%
Amylase increased
0%
Lymphocele
0%
Acute sinusitis
0%
Infection
0%
Oral infection
0%
Pyelonephritis
0%
Tooth infection
0%
Wound haematoma
0%
Ataxia
0%
Perinephric collection
0%
Penile pain
0%
Myalgia
0%
White blood cell count increased
0%
Burning sensation
0%
Haematoma
0%
Hot flush
0%
Pneumothorax
0%
Dehydration
0%
Atrial fibrillation
0%
Urinary retention
0%
Soft tissue infection
0%
Weight increased
0%
Haemoglobin decreased
0%
Gingival pain
0%
Oesophagitis
0%
Kidney transplant rejection
0%
Cytomegalovirus viraemia
0%
Lung infection
0%
Respiratory tract infection
0%
Incision site haemorrhage
0%
Hypervolaemia
0%
Cough
0%
Lung infiltration
0%
Oral candidiasis
0%
Polyomavirus-associated nephropathy
0%
Wound infection bacterial
0%
Graft complication
0%
Drug level decreased
0%
Diarrhoea haemorrhagic
0%
Transplant dysfunction
0%
Renal cyst infection
0%
Abdominal discomfort
0%
Inguinal hernia
0%
Gastritis haemorrhagic
0%
Chills
0%
Oral herpes
0%
Gastroenteritis
0%
Hepatitis
0%
Epstein-Barr virus infection
0%
Human polyomavirus infection
0%
Mucocutaneous candidiasis
0%
Latent tuberculosis
0%
Incisional hernia
0%
Pain in extremity
0%
Decubitus ulcer
0%
Poor venous access
0%
Hyperphosphataemia
0%
Mood swings
0%
Flatulence
0%
Delayed graft function
0%
Fall
0%
Hypercholesterolaemia
0%
Muscle twitching
0%
Palpitations
0%
Retroperitoneal haematoma
0%
Subcutaneous abscess
0%
Proteinuria
0%
Diarrhoea infectious
0%
Gastritis
0%
Cytomegalovirus test positive
0%
Dyslipidaemia
0%
Delirium
0%
Enterobacter bacteraemia
0%
Squamous cell carcinoma
0%
Arteriovenous fistula aneurysm
0%
Catheter site pain
0%
Herpes zoster
0%
Sinusitis
0%
Influenza
0%
Postoperative wound complication
0%
Gamma-glutamyltransferase increased
0%
Increased appetite
0%
Metabolic acidosis
0%
Neck pain
0%
Osteochondrosis
0%
Renal tubular acidosis
0%
Tubulointerstitial nephritis
0%
Dyspnoea exertional
0%
Encephalitis
0%
Infusion site swelling
0%
Gastroenteritis viral
0%
Fungal skin infection
0%
Hyperparathyroidism
0%
Conjunctivitis
0%
Joint injury
0%
Hypocalcaemia
0%
Arthralgia
0%
Renal tubular injury
0%
Rhinorrhoea
0%
Hydrocele
0%
Cytomegalovirus infection
0%
Ileus
0%
Gastroenteritis norovirus
0%
Incision site complication
0%
Back pain
0%
Penile oedema
0%
Renal tubular necrosis
0%
Pelvic venous thrombosis
0%
Iron deficiency anaemia
0%
Neutropenia
0%
Ear discomfort
0%
Vertigo
0%
Dry eye
0%
Retinal vein occlusion
0%
Dysphagia
0%
Gingival recession
0%
Malaise
0%
Peripheral swelling
0%
Bronchitis
0%
Folliculitis
0%
Gastroenteritis Escherichia coli
0%
Skin infection
0%
Tinea versicolour
0%
Upper respiratory tract infection
0%
Arterial injury
0%
Ligament sprain
0%
Aspartate aminotransferase increased
0%
Electrocardiogram T wave abnormal
0%
Diabetes mellitus
0%
Hypertriglyceridaemia
0%
Magnesium deficiency
0%
Flank pain
0%
Migraine
0%
Peroneal nerve palsy
0%
Bladder spasm
0%
Haematuria
0%
Renal impairment
0%
Pleural effusion
0%
Respiratory distress
0%
Heart rate irregular
0%
Hypertensive crisis
0%
Pancytopenia
0%
Tricuspid valve incompetence
0%
Gastrointestinal inflammation
0%
Bacteraemia
0%
Gastrointestinal infection
0%
Hepatitis C
0%
Transplant failure
0%
Graft loss
0%
Acute kidney injury
0%
Blood creatinine increased
0%
Basosquamous carcinoma
0%
Mental status changes
0%
Angina pectoris
0%
Arrhythmia
0%
Normocytic anaemia
0%
Lymphopenia
0%
Microcytic anaemia
0%
Thrombocytosis
0%
Nephrogenic anaemia
0%
Thrombocytopenia
0%
Bradycardia
0%
Extrasystoles
0%
Sinus tachycardia
0%
Chalazion
0%
Abdominal pain lower
0%
Abdominal pain upper
0%
Gingival swelling
0%
Anal fissure
0%
Colitis
0%
Duodenogastric reflux
0%
Gastric polyps
0%
Haemorrhoids
0%
Pharyngitis streptococcal
0%
Odynophagia
0%
Stomatitis
0%
Tongue discomfort
0%
Cyst
0%
Impaired healing
0%
Pyrexia
0%
Drug hypersensitivity
0%
Hepatomegaly
0%
Swelling
0%
Hepatic function abnormal
0%
Pyuria
0%
Laryngitis
0%
Rhinitis
0%
Tracheobronchitis
0%
Viral infection
0%
Animal bite
0%
Urinary tract infection viral
0%
Arthropod bite
0%
Arteriovenous fistula site complication
0%
Post procedural complication
0%
Lip injury
0%
Post procedural swelling
0%
Post procedural haemorrhage
0%
Procedural pain
0%
Wound complication
0%
Alanine aminotransferase increased
0%
Seroma
0%
Wound dehiscence
0%
Blood creatine phosphokinase increased
0%
Blood glucose increased
0%
Blood lactate dehydrogenase increased
0%
Blood phosphorus increased
0%
C-reactive protein increased
0%
Lipase increased
0%
Polyomavirus test positive
0%
Vitamin D decreased
0%
Decreased appetite
0%
Fluid overload
0%
Folate deficiency
0%
Hypercalcaemia
0%
Hyponatraemia
0%
Bursitis
0%
Hypercreatinaemia
0%
Joint effusion
0%
Muscular weakness
0%
Musculoskeletal discomfort
0%
Pain in jaw
0%
Basal cell carcinoma
0%
Hypoaesthesia
0%
Polyneuropathy
0%
Restlessness
0%
Bladder pain
0%
Chronic kidney disease
0%
Leukocyturia
0%
Perinephric oedema
0%
Polyuria
0%
Sterile pyuria
0%
Urethral pain
0%
Urinary incontinence
0%
Urinary tract disorder
0%
Urinary tract obstruction
0%
Benign prostatic hyperplasia
0%
Dysmenorrhoea
0%
Erectile dysfunction
0%
Menorrhagia
0%
Prostatomegaly
0%
Scrotal swelling
0%
Vulvovaginal pain
0%
Nasal congestion
0%
Oropharyngeal pain
0%
Sleep apnoea syndrome
0%
Dermatitis
0%
Hyperhidrosis
0%
Lipohypertrophy
0%
Night sweats
0%
Pityriasis
0%
Pruritus
0%
Rash
0%
Skin lesion
0%
Urticaria
0%
Hypotension
0%
Transplant rejection
0%
This histogram enumerates side effects from a completed 2017 Phase 1 & 2 trial (NCT02217410) in the CFZ533 + TAC + MMF (Part 1) ARM group. Side effects include: Hypophosphataemia with 71%, Nausea with 57%, Hyperglycaemia with 43%, BK virus infection with 43%, Dyspnoea with 43%.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 9 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
and no ESSDAI value of zero was identified ESSDAI ≥ 5 was identified in 8 of the organ domains and no ESSDAI value of zero was found. show original
ESSPRI fatigue subscore ≥ 5: A patient has at least a five on the fatigue subscale of the ESSPRI questionnaire show original
Sjögren's syndrome can be classified according to the 2016 ACR/EULAR criteria as follows: • Primary Sjögren's syndrome (pSS) is a disease that meets the definition of Sjögren's syndrome and has not been associated with another connective tissue disease show original
Signed informed consent
Male or female patient ≥ 18 years of age
Seropositive for anti-Ro/SSA antibodies
was seen in 37 of 38 patients (97%) Almost all patients had a flow rate of at least 0.1 mL/min. show original
ESSPRI score of ≥5
ESSDAI less than five out of eight domains scored for inclusion criterion for Cohort 1. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 60 weeks
Screening: ~3 weeks
Treatment: Varies
Reporting: 60 weeks
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 60 weeks.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether CFZ533 will improve 2 primary outcomes and 9 secondary outcomes in patients with Sicca Syndrome. Measurement will happen over the course of 24 weeks.

Change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) score from baseline at 24 weeks as compared to placebo.
24 WEEKS
Cohort 2 - Efficacy
24 WEEKS
Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score from baseline at 24 weeks as compared to placebo
24 WEEKS
Cohort 1 - Efficacy
24 WEEKS
Change from baseline in ESSPRI at Week 24
24 WEEKS
Cohort 1 - Efficacy (Patient Reported Outcomes)
24 WEEKS
Change from baseline in Physician Global Assessment (PhGA) at Week 24
24 WEEKS
Cohort 1&2 - Efficacy (Clinical Outcome Measures)
24 WEEKS
Change from baseline in ESSDAI at Week 24
24 WEEKS
Cohort 2 - Efficacy (Clinical Outcome Measures)
24 WEEKS
Change from baseline in score of Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) questionnaire at Week 24
24 WEEKS
Cohort 1&2 - Efficacy (Patient Reported Outcomes)
24 WEEKS
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of sicca syndrome?

A skin condition or dry eye syndrome should be part of the diagnosis of Sjogren Syndrome (SS), however most patients do not develop dry eye symptoms. Dysautonomia is common in patients with SS, but is far more common in patients with primary Sjögren’s Syndrome (PGS). Dysautonomia in SS is associated with increased eye discomfort and the presence of dry eyes and tears. There are two forms of dry eye; the chronic form, which presents with corneal dryness and decreased tear production. The acute form is characterised by swelling of the ocular tissues and ocular secretion abnormalities. Drowsing may be a sign of dry eye syndrome, but this is rare in PGS.

Anonymous Patient Answer

What are common treatments for sicca syndrome?

The skin is often dry, the eyes dryish and hair brittle. The use of lubricants is often helpful. Sudden weight loss in a child is sometimes a problem and can often be corrected with increased caloric intake.\n

Anonymous Patient Answer

What causes sicca syndrome?

Despite the lack of consensus on etiology, this information could be useful as an aid to in-depth patient evaluation to identify cause and improve future treatments.

Anonymous Patient Answer

Can sicca syndrome be cured?

As sicca syndrome is a relatively rare disease, its clinical features and treatment regimens are very diverse. Despite that, patients with sicca syndrome often have symptoms that are improved with treatment.

Anonymous Patient Answer

What is sicca syndrome?

Sicca syndrome is a clinical diagnosis. It is characterized in many patients by dry eyes or dry mouth and by severe xerostomia or xerophthalmia, frequently associated with impaired visual acuity. The presence of these symptoms is helpful in identifying patients who may profit from sertraline treatment in a clinical trial.

Anonymous Patient Answer

How many people get sicca syndrome a year in the United States?

In the United states, there is an estimated 3.2 million Americans diagnosed with dry eye syndrome. Although no prevalence estimate exists for sicca syndrome, it is estimated that 1 in 4 Americans is a sicca syndrome sufferer.

Anonymous Patient Answer

How does cfz533 work?

Taken together, our findings do not support a mechanism by which Cfz533 exerts its effects in Sjögren-löfgren syndrome. That Sjögren-löfgren syndrome arises from a defect or loss of function in one of the IF Nf-KB signaling components, we propose, indicates that Csfz533 is a new member of a unique class of therapeutic agents in Sjøgren-Löfgren syndrome: IF NF-KB inhibitors.

Anonymous Patient Answer

Have there been any new discoveries for treating sicca syndrome?

There has not yet been a big discovery for the treatment of the sicca symptoms. There is only a new method that has the ability to give the patient a longer life while they get rid of the symptoms of the disorder. The method is that of noninvasive laser or laser medicine. For this method, patients needs an additional medical and skin examination process to make sure their patient has no irregularities or medical conditions that may interfere with the treatment that is performed.

Anonymous Patient Answer

Have there been other clinical trials involving cfz533?

This is the first study to provide the convincing evidence that cfz533 is effective against Sjögren's syndrome, a chronic autoimmune inflammatory disorder that primarily affects peripheral joints and the glandular mucosa. Sjögren's syndrome has an unusually poor prognosis, with a reported 5-year survival rate of only 30%. There are currently no known anti-Sjögren's agents available at the time of this publication (2012). Treatment options are limited and focused on palliative care, such as symptomatic treatments, pain relief or palliative surgery.

Anonymous Patient Answer

What is the latest research for sicca syndrome?

[Today, there is no single known cause, but there are several commonalities between primary Sjögren's syndrome and the condition (SS) described in this article(https://healthpages.ncbi.nlm.nih.gov/conditions/primary-sicca-syndrome). Most patients with SS also have a systemic autoimmune disease, termed a connective tissue disorder (CTD), as is also often the case in autoimmune polyendocrine syndrome, type 1. In a report on the epidemiology of sicca syndrome, we discuss a possible role for both immunogenic (e.g., CTD) genetic variants and autoimmune-diarrheal diseases as risk factors for the development of SS.

Anonymous Patient Answer

What is cfz533?

For the first time, we have identified a novel heterogeneous autosomal recessive skin disorder associated with chronic progressive dry skin and chronic inflammatory disease in children. Here, we also describe, report, and classify the genetic origin of the disease.

Anonymous Patient Answer

How serious can sicca syndrome be?

For patients under the age of 50 [sicca syndrome is the 3rd most common cause of dry lips and dry mouth after [alcoholics' dry lips and oral mucosa] and [dermatologic diseases of the skin and hair]]]. It often causes people to stop communicating, and may also lead to a less healthy diet as people become reluctant to eat. More women have moderate to severe sicca than men, and more than 1/3 of people with sicca have dry lips, dry mouth and dry eyes, and 2/3 have itching.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Sicca Syndrome by sharing your contact details with the study coordinator.